Insmed Inc’s recent filing unveils that its Chief Financial Officer Bonstein Sara unloaded Company’s shares for reported $5.88 million on Jun 23 ’25. In the deal valued at $101.78 per share,57,765 shares were sold. As a result of this transaction, Bonstein Sara now holds 93,536 shares worth roughly $9.31 million.
Then, Bonstein Sara bought 57,765 shares, generating $5,877,434 in total proceeds.
Before that, Wise John Drayton bought 20,000 shares. Insmed Inc shares valued at $2,099,400 were divested by the Former Officer at a price of $104.97 per share.
Jefferies initiated its Insmed Inc [INSM] rating to a Buy in a research note published on May 13, 2025; the price target was $105. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late February with a ‘”an Outperform”‘ rating. Truist began covering INSM with “Buy” recommendation on April 23, 2024. Wolfe Research started covering the stock on February 15, 2024. It rated INSM as “an Outperform”.
Price Performance Review of INSM
On Friday, Insmed Inc [NASDAQ:INSM] saw its stock fall -2.21% to $99.49. Over the last five days, the stock has lost -3.11%. Insmed Inc shares have risen nearly 42.72% since the year began. Nevertheless, the stocks have risen 44.10% over the past one year. While a 52-week high of $106.83 was reached on 06/25/25, a 52-week low of $60.40 was recorded on 04/09/25.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 98.14, which if violated will result in even more drops to 96.79. On the upside, there is a resistance level at 101.54. A further resistance level may holdings at 103.60.
How much short interest is there in Insmed Inc?
A steep rise in short interest was recorded in Insmed Inc stocks on 2025-06-13, dropping by -4.82 million shares to a total of 11.65 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 16.47 million shares. There was a decline of -41.35%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 08, 2023 when Wells Fargo began covering the stock and recommended ‘”an Overweight”‘ rating along with a $55 price target.
